Advicenne wins Spanish reimbursement for Sibnayal in dRTA

21 July 2026

French pharma Advicenne (Euronext Paris: ALDV), which is developing treatments for people suffering from rare kidney diseases, announced that Sibnayal (a prolonged-release combination of potassium citrate and potassium bicarbonate) is now reimbursed in Spain for the treatment of distal renal tubular acidosis (dRTA).

The reimbursed prices of Sibnayal in Spain are: 409.84 euros ($468.86) including tax for Sibnayal 24 mEq 847mg/1582 mg; and 136.62 euros including tax for Sibnayal® 8 mEq 282 mg/527 mg

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK